155 related articles for article (PubMed ID: 38701024)
1. The effectiveness and value of sotatercept for pulmonary arterial hypertension: A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council.
Nikitin D; Lin GA; Whittington MD; Nhan E; Kayali Y; Rind DM; Pearson SD; Agboola F
J Manag Care Spec Pharm; 2024 May; 30(5):491-495. PubMed ID: 38701024
[No Abstract] [Full Text] [Related]
2. KarXT for schizophrenia-effectiveness and value: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
McKenna A; Tice JA; Whittington MD; Wright AC; Richardson M; Raymond FR; Pearson SD; Rind DM; Agboola F
J Manag Care Spec Pharm; 2024 Jun; 30(6):624-628. PubMed ID: 38824622
[No Abstract] [Full Text] [Related]
3. Cost-Effectiveness of Combination Therapy for Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension.
Tran-Duy A; Morrisroe K; Clarke P; Stevens W; Proudman S; Sahhar J; Nikpour M;
J Am Heart Assoc; 2021 Apr; 10(7):e015816. PubMed ID: 33759539
[TBL] [Abstract][Full Text] [Related]
4. Sotatercept (Winrevair) for pulmonary arterial hypertension.
Med Lett Drugs Ther; 2024 May; 66(1702):73-75. PubMed ID: 38696310
[No Abstract] [Full Text] [Related]
5. The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council.
Nikitin D; Makam AN; Suh K; McKenna A; Carlson JJ; Richardson M; Rind DM; Pearson SD
J Manag Care Spec Pharm; 2023 Feb; 29(2):216-221. PubMed ID: 36705279
[No Abstract] [Full Text] [Related]
6. The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council.
Wright AC; Beaudoin FL; McQueen RB; Yeung K; Moradi A; Herron-Smith S; Gutierrez E; Lin GA; Pearson SD
J Manag Care Spec Pharm; 2023 Jun; 29(6):692-698. PubMed ID: 37276043
[No Abstract] [Full Text] [Related]
7. Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms.
Mathai SC; Hemnes AR; Manaker S; Anguiano RH; Dean BB; Saundankar V; Classi P; Nelsen AC; Gordon K; Ventetuolo CE
Ann Am Thorac Soc; 2019 Jul; 16(7):797-806. PubMed ID: 30865835
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of pulmonary arterial hypertension drugs in treatment-naive patients: a network meta-analysis.
Petrovič M; Locatelli I
J Comp Eff Res; 2020 Jan; 9(1):7-22. PubMed ID: 31845591
[No Abstract] [Full Text] [Related]
9. A Summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
Otuonye IS; Banken R; Kumar VM; Pearson SD
J Manag Care Spec Pharm; 2019 Jun; 25(6):630-634. PubMed ID: 31134864
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of pulmonary arterial hypertension in the Camerino area of central Italy and savings resulting from generic bosentan.
Natali S; Palmieri M; Polidori C
Eur J Hosp Pharm; 2020 Mar; 27(2):100-102. PubMed ID: 32133136
[TBL] [Abstract][Full Text] [Related]
11. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
Hoeper MM; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Souza R; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Xu Y; Miller B; Fowler M; Butler J; Koglin J; de Oliveira Pena J; Humbert M;
N Engl J Med; 2023 Apr; 388(16):1478-1490. PubMed ID: 36877098
[TBL] [Abstract][Full Text] [Related]
12. Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials.
Scott JV; Garnett CE; Kanwar MK; Stockbridge NL; Benza RL
Am J Respir Crit Care Med; 2021 Mar; 203(6):726-736. PubMed ID: 32937078
[No Abstract] [Full Text] [Related]
13. Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman A; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; Barnes J; Linde PG; de Oliveira Pena J; Badesch DB;
N Engl J Med; 2021 Apr; 384(13):1204-1215. PubMed ID: 33789009
[TBL] [Abstract][Full Text] [Related]
14. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
15. Management options for children with attention-deficit/hyperactivity disorder: a regional perspective on value.
Ollendorf DA; Migliaccio-Walle K; Colby JA; Pearson SD
J Comp Eff Res; 2013 May; 2(3):261-71. PubMed ID: 24236625
[TBL] [Abstract][Full Text] [Related]
16. High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach.
Shah NB; Mitchell RE; Proctor ST; Choi L; DeClercq J; Jolly JA; Hemnes AR; Zuckerman AD
PLoS One; 2019; 14(6):e0217798. PubMed ID: 31170217
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and persistence with selexipag in pulmonary arterial hypertension in the real-life setting.
Del Pozo R; Blanco I; López-Meseguer M; Escribano-Subías P; Cruz Utrilla A
Eur J Intern Med; 2023 May; 111():140-142. PubMed ID: 36720652
[No Abstract] [Full Text] [Related]
18. Pharmacotherapy of refractory pulmonary arterial hypertension.
Ahmed MS; Ghallab M; Ostrow T; Nashawi M; Alagha Z; Levine A; Aronow WS; Lanier GM
Expert Opin Pharmacother; 2023; 24(17):1861-1874. PubMed ID: 37698041
[TBL] [Abstract][Full Text] [Related]
19. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman AB; Ghofrani HA; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; de Oliveira Pena J; Badesch DB
Eur Respir J; 2023 Jan; 61(1):. PubMed ID: 36041750
[TBL] [Abstract][Full Text] [Related]
20. Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management.
Correale M; Tricarico L; Grazioli D; Formica ES; Petrucci R; Persichella P; Di Biase M; Brunetti ND
Cardiovasc Drugs Ther; 2019 Dec; 33(6):725-738. PubMed ID: 31811420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
